| Tabs | tablets |
|---|---|
| PSVT | Paroxysmal Supra-Ventricular Tachycardia ? Tx 1. Carotid ... |
| WPW Syndrome | Wolff-Parkinson-White Syndrome ? CIx 1. Drugs; AV Conduct... |
| CONVINCE | Controlled Onset Verapamil Investigation of Cardiovascular Endpoints |
| DAVIT | Danish Verapamil Infarction Trial |
| V | Verapamil |
|---|---|
| VER | Verapamil |
| VP | Verapamil |
| VRP | Verapamil |
| VPL | verapamil |
| verapamil | <drug> A calcium channel blocking drug, used as a coronary vasodilator and antiarrhythmic. Pharmacologic action: Calcium channel blockade, direct, potent negative chronotrope and inotrope, slows conduction in AV node, systemic and coronary vasodilation. Uses: Supraventricular tachycardias. Dose: 2.5 - 5.0 mg IV over 1-2 minutes May repeat at 5.0 - 10 mg every 15-30 minutes until 30 mg total dose. Onset: 3 - 5 min. Potential complications: Hypotension due to vasodilation and depressed contractility. Treat with calcium; bradycardia, AV block can be exacerbated, contraindicated with congestive heart failure, synergistic interaction with beta blockers. Note: Administration of verapamil to a patient with ventricular tachycardia can be lethal. Verapamil can accelerate heart rate and decrease blood pressure, especially in patients with Wolff-Parkinson-White and wide-complex tachycardia. (12 Mar 2000) |
|---|---|
| tablets | Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (12 Dec 1998) |
| tablets, enteric-coated | Tablets coated with material that delays release of the medication until after they leave the stomach. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|